value-based contracts

Despite hype, private payers slow to adopt oncology value-based modelsOncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.
Value-based payment update: Where we are and who is most successful
Value-based payment update: Where we are and who is most successfulWhile these types of programs have been in place for several years, it can be difficult to gauge who is using them and how, and whether they are achieving their intended goal.
Five questions for CVS Health’s Troyen A. Brennan, MD, MPHCVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.
Monetary benefits from value-based diabetes plans take timeValue-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Value-based drug contracting shifts risk to manufacturersValue-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Opinion: Top 2 takeaways from Asembia Specialty Pharmacy SummitThe conference raised important points about value-based contracts and the specialty pharmacy space.
Top pharmacy challenges of 2017
Top pharmacy challenges of 2017High drug prices continue to plague payers, but various contributing factors intensify the problem.
Launching a provider-sponsored health plan: 5 things to knowAs health systems and physician groups marshal resources to launch their own plans, they must consider whether they have the necessary building blocks to successfully make the leap, how integrated a model they will pursue and whether they will build, buy or partner strategy.
Four critical components for successful, value-based pharma contractsDespite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
New agreement supports value-based pharma contractingIndustry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.